A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Pancreatic Cancer

In brief

This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.

Key facts

Study ID
NCT01505530
Run by
Eli Lilly and Company
People needed
125
Starts
2011-12-01
Expected to finish
2016-01-01
Last updated by the study team
2019-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.